Download PDF
Z Gastroenterol 2018; 56(06): 578-582
DOI: 10.1055/a-0581-5640
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Sequence therapy in metastatic pancreatic cancer

Sequenztherapie beim metastasierten Pankreaskarzinom
Oliver Waidmann
1   Medizinische Klinik 1, Schwerpunkt Gastroenterologie und Hepatologie, Universitätsklinikum Frankfurt, Frankfurt/Main, Germany
,
Uwe Pelzer
2   Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
,
Stefan Boeck
3   Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern, München, Germany
,
Dirk-Thomas Waldschmidt
4   Klinik für Gastroenterologie und Hepatologie, Uniklinik Köln, Köln, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients with metastatic pancreatic cancer. Within the last years, new combination therapies have been established for first-line treatment, which significantly improve overall survival in comparison to gemcitabine monotherapy. Furthermore, new second-line therapies have been identified, which significantly improve overall survival. The current manuscript summarizes briefly standard of care first- and second-line chemotherapies and discusses possible treatment sequences.

Zusammenfassung

Das Pankreaskarzinom ist eine der häufigsten malignen Tumorerkrankungen des oberen Gastrointestinaltraktes. Viele Jahre lange war Gemcitabin die einzige therapeutische Option für Patienten mit metastasiertem Pankreaskarzinom. In den letzten Jahren wurden jedoch neue Chemotherapiekombinationen in der Erstlinientherapie etabliert, die die Prognose der Patienten im Vergleich zur Gemcitabinmonotherapie signifikant verbessern. Zudem wurden neue Zweitlinientherapien identifiziert, die das Überleben auch signifikant verlängern. Diese Arbeit soll einen kurzen Überblick über die aktuellen Erst- und Zweitlinientherapien beim metastasierten Pankreaskarzinom geben und diskutiert mögliche Therapiesequenzen.

Key words

pancreatic cancer - systemic chemotherapy - chemotherapy - sequence therapy - metastatic pancreatic cancer - gemcitabine

Schlüsselwörter

Pankreaskarzinom - Systemische Chemotherapie - Chemo therapie - Sequenztherapie - Metastasiertes Pankreaskarzinom - Gemcitabin
 

  • References

  • 1 Robert-Koch-Institut. Bericht zum Krebsgeschehen in Deutschland 2016. Available at: http://edoc.rki.de/documents/rki_fv/renGkGzAqwKc2/PDF/28oaKVmif0wDk.pdf
    PubMedGoogle Scholar
  • 2 Tempero MA, Malafa MP, Behrman SW. et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2014; 12: 1083-1093
    CrossrefPubMedGoogle Scholar
  • 3 Ducreux M, Cuhna AS, Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v56-v68
    CrossrefPubMedGoogle Scholar
  • 4 Seufferlein T, Porzner M, Becker T. et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol 2013; 51: 1395-1440
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
    CrossrefPubMedGoogle Scholar
  • 6 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
    Google Scholar
  • 7 Stein SM, James ES, Deng Y. et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114: 737-743
    CrossrefPubMedGoogle Scholar
  • 8 Moore MJ, Goldstein D, Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
    CrossrefPubMedGoogle Scholar
  • 9 Haas M, Boeck SH, Siveke JT. et al. Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX. J Clin Oncol 2017; 35: 4108
    CrossrefPubMedGoogle Scholar
  • 10 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
    CrossrefPubMedGoogle Scholar
  • 11 Abrams TA, Meyer G, Meyerhardt JA. et al. Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic cancer. Oncologist 2017; 22: 925-933
    CrossrefPubMedGoogle Scholar
  • 12 Pelzer U, Schwaner I, Stieler J. et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-1681
    CrossrefPubMedGoogle Scholar
  • 13 Chiorean EG, Von Hoff DD, Tabernero J. et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer 2016; 115: 188-194
    CrossrefPubMedGoogle Scholar
  • 14 Oettle H, Riess H, Stieler JM. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-2429
    CrossrefPubMedGoogle Scholar
  • 15 Gill S, Ko YJ, Cripps C. et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34: 3914-3920
    CrossrefPubMedGoogle Scholar
  • 16 Yoo C, Hwang JY, Kim JE. et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658-1663
    CrossrefPubMedGoogle Scholar
  • 17 Gebbia V, Maiello E, Giuliani F. et al. Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33: 461-464
    CrossrefPubMedGoogle Scholar
  • 18 Zaniboni A, Aitini E, Barni S. et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69: 1641-1645
    CrossrefPubMedGoogle Scholar
  • 19 Wang-Gillam A, Li CP, Bodoky G. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545-557
    CrossrefPubMedGoogle Scholar
  • 20 Pelzer U, Blanc JF, Melisi D. et al. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. Br J Cancer 2017; 116: 1247-1253
    CrossrefPubMedGoogle Scholar
  • 21 Bachet JB, Hammel P, Desramé J. et al. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Lancet Gastroenterol Hepatol 2017; 2: 337-346
    CrossrefPubMedGoogle Scholar
  • 22 Viaud J, Brac C, Artru P. et al. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: a retrospective study. Dig Liver Dis 2017; 49: 692-696
    CrossrefPubMedGoogle Scholar
  • 23 da Rocha Lino A, Abrahão CM, Brandão RM. et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol 2015; 6: 511-515
    PubMedGoogle Scholar
  • 24 Portal A, Pernot S, Tougeron D. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 2015; 113: 989-995
    CrossrefPubMedGoogle Scholar
  • 25 Heinemann V, Vehling-Kaiser U, Waldschmidt D. et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104). Gut 2013; 62: 751-759
    CrossrefPubMedGoogle Scholar